Re: First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma with Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial Editorial Comment

被引：2
|
作者：
Richie, Jerome P.
机构：
来源：
JOURNAL OF UROLOGY | 2012年 / 188卷 / 01期
关键词：
D O I：
10.1016/j.juro.2012.03.060
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：115 / 116
页数：2
相关论文
共 50 条
  • [21] Valproate in Combination with Rituximab and CHOP As First Line Therapy in Diffuse Large B-Cell Lymphoma (VALFRID): Preliminary Results from a Phase I Trial with a Dose Expansion Cohort
    Drott, Kristina
    Hagberg, Hans
    Relander, Thomas
    Graffman, Cecilia
    Drott, Johan
    Jerkeman, Mats
    BLOOD, 2015, 126 (23)
  • [22] Bendamustine in association with rituximab for first-line treatment of diffuse large B-cell lymphoma in frail patients ineligible for R-CHOP/R-CHOP-like treatments
    Castelli, Roberto
    Gidaro, Antonio
    Deliliers, Giorgio L.
    Bergamaschini, Luigi
    ANTI-CANCER DRUGS, 2021, 32 (03) : 323 - 329
  • [23] Rituximab and Bendamustine for first-line treatment of frail or elderly patients with aggressive B-cell lymphoma: first results of the German prospective phase-II BRENDA trial
    Braulke, F.
    Zettl, F.
    Ziepert, M.
    Viardot, A.
    Kahl, C.
    Prange-Krex, G.
    Korfel, A.
    Dreyling, M.
    Illmer, T.
    Birkmann, J.
    Wedding, U.
    Reichert, D.
    de Wit, M.
    Hartmann, F.
    Hurtz, H. -J.
    Poeschel, V
    Schmitz, N.
    Witzens-Harig, M.
    Klapper, W.
    Rosenwald, A.
    Wulf, G.
    Pfreundschuh, M.
    Altmann, B.
    Truemper, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 4 - 5
  • [24] Phase II open study using Rituximab (MabThera) plus CHOP in treatment of pts with diffuse large B-cell Lymphoma (DLCL)
    Shahrasbi, A.
    Raafat, J.
    Latifzadeh, Z.
    ANNALS OF ONCOLOGY, 2004, 15 : 156 - 156
  • [25] A Prospective, Observational Study on the Safety and Effectiveness of Rituximab Plus Chemotherapy As the First-Line Treatment of Diffuse Large B-Cell Lymphoma
    Feng, Jifeng
    Wu, Jianqiu
    Song, Yongping
    Su, Liping
    Zhang, Mingzhi
    Li, Wei
    Hu, Yu
    Zhang, Xiaohong
    Gao, Yuhuan
    Feng, Ru
    Wang, Wei
    Niu, Zuoxing
    Peng, Jiewen
    Li, Xiaolin
    Ouyang, Xuenong
    Wu, Changing
    Zhang, Weijing
    Zeng, Yun
    Xiao, Zhen
    Liang, Yingmin
    Zhuang, Yongzhi
    Wang, Jishi
    Sun, Zimin
    Bai, Hai
    Cui, Tongjian
    BLOOD, 2014, 124 (21)
  • [26] A Phase II Study of the Combination Chemotherapy Consisted of Rituximab and THP-COP Regimen as First-Line Treatment for Patients with Diffuse Large B-Cell Lymphoma.
    Tsurumi, Hisashi
    Goto, Naoe
    Hara, Takeshi
    Kasahara, Senji
    Kanemura, Nobuhiro
    Kitagawa, Junichi
    Yoshikawa, Takeshi
    Yamada, Toshiki
    Sawada, Michio
    Takahashi, Takeshi
    Takami, Tsuyoshi
    Moriwaki, Hisataka
    BLOOD, 2008, 112 (11) : 1231 - 1231
  • [27] Rituximab biosimilar RTXM83 versus reference rituximab in combination with CHOP as first-line treatment for diffuse large B-cell lymphoma: a randomized, double-blind study
    Candelaria, Myrna
    Gonzalez, Derlis E.
    Delamain, Marcia Torresan
    Bar, Daniel Oscar
    Beniwal, Surender Kumar
    Dasappa, Lokanatha
    Flores, David Hugo
    Querol, John
    Guan, Toh See
    Lipatov, Oleg Nikolaevich
    Volodicheva, Elena Mikhailovna
    Patel, Moosa
    Nodehi, Sayyed Reza Safaee
    Fogliatto, Laura
    Paravisini, Alexandra
    Perez Diaz, Luis
    Bhatt, N.
    Bhattacharyya, S.
    Mukhopadhyay, A.
    Salvatierra, A.
    Radhakrishnan, V.
    Bhurani, D.
    Jasuja, S.
    Kowalyszyn, R. D.
    da Silva Araujo, S. Shusterschitz
    Syafei, S.
    Caffaro, J.
    De Stefano, G.
    Garcia, J. J.
    Ciliao Munhoz, E.
    Bermudez, C.
    Gin, G. Gin
    Raman, R.
    Villegas, E. M.
    Martinez-Lapus, F. G. P.
    Molina Barrios, G. R.
    Tiangco, B. J.
    Viktorovich, P. A.
    Moiseevich, M. G.
    Avila, G. I.
    Munoz, M.
    Saslavsky, M. M.
    Beguelin, G. Z.
    Fogliatto, L.
    Salvino de Araujo, A.
    Pereira, J.
    Rodrigues de Oliveira, J. S.
    Luiz da Silva, R.
    de Mattos, E. R.
    Santi, P. Xavier
    LEUKEMIA & LYMPHOMA, 2019, 60 (14) : 3375 - 3385
  • [28] A RETROSPECTIVE ANALYSIS COMPARING RITUXIMAB BIOSIMILAR (HLX01) VERSUS ORIGINATOR (RITUXAN) IN COMBINATION WITH CHOP AS FIRST-LINE TREATMENT FOR DIFFUSE LARGE B-CELL LYMPHOMA
    Huo, Zhongjun
    Zhao, Jiajia
    Chen, Fang
    Chao, Zhi
    Zheng, Haifeng
    Liu, Ping
    Zhou, Dan
    Zhang, Lu
    Wu, Lingzhen
    Yang, Wenqun
    Tan, Zhenqing
    Zhu, Kaibo
    Luo, Zimian
    JOURNAL OF INVESTIGATIVE MEDICINE, 2023, 71 : 15 - 16
  • [29] Phase III trial of rituximab-CHOP (R-CHOP) vs. CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL).
    Habermann, TM
    Weller, EA
    Morrison, VA
    Cassileth, PA
    Cohn, JB
    Dakhil, SR
    Gascoyne, RD
    Woda, B
    Fisher, RI
    Peterson, BA
    Horning, SJ
    BLOOD, 2003, 102 (11) : 6A - 6A
  • [30] A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806
    Persky, Daniel O.
    Li, Hongli
    Rimsza, Lisa M.
    Barr, Paul M.
    Popplewell, Leslie L.
    Bane, Charles L.
    Von Gehr, Ann
    LeBlanc, Michael
    Fisher, Richard I.
    Smith, Sonali M.
    Friedberg, Jonathan W.
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (04) : 486 - 493
12345